Ansa Biotechnologies raises $71.5M Series C led by Blue Water

· VC Investment

TLDR

  • Ansa Biotechnologies closed a $71.5M Series C led by Blue Water, taking total funding to $211M, the company said.1
  • New investors are Illumina Ventures, BEVC, Lightscape Partners and Agent Capital; valuation and revenue were not disclosed.1
  • Ansa says it quadrupled capacity in a year; its guarantee makes late qualifying orders free, excluding partner orders.13

Ansa Biotechnologies, an Emeryville, California, maker of synthetic DNA built with an enzymatic process, announced on 18 November 2026 the closing of an oversubscribed $71.5M Series C, bringing total funding to $211M.1 Blue Water Life Science Advisors led. New investors are Illumina Ventures, BEVC, Lightscape Partners and Agent Capital, joined by existing backers Cerberus Ventures, Fall Line Capital, Dauntless Ventures and Altitude Life Science Ventures.1 Nick Naclerio of Illumina Ventures, life science tools executive Brad Crutchfield (independent director) and Nate Cornell of Blue Water join the board, BEVC co-founder Rowan Chapman becomes a board observer, and Matthew McManus steps down.1 The release gives no valuation, revenue or per-investor amounts. Lightscape, in its own post, says it took part "alongside Cerberus Ventures".2

Ansa sells sequence-perfect clonal DNA up to 50 kilobases and sequence-verified linear double-stranded fragments, and says every order undergoes biosecurity screening.1 Its On-Time Guarantee means that if the ship date is missed, "the entire order is free".1 Captables reports, from Ansa's FAQ, that the guarantee covers only qualifying orders placed directly with Ansa, not partner orders or sequences labelled "Let's Try".3 The company says capacity quadrupled "during the past year", a company-reported claim.1 It pitches demand as coming from AI-enabled drug discovery, where designs must be built as physical DNA to be tested.1 In a September release with Integrated DNA Technologies (IDT), the pair said more than 400 institutions in 33 countries had ordered Ansa DNA through IDT since January, with a 97 per cent fulfilment rate, also company-reported.4

The round extends a run of financings. Northpond Ventures led a $68M Series A in April 2022, with Blue Water among the participants.5 Cerberus Ventures led a $54.4M Series B announced on 1 October 2025, made up of $45.2M closed and $9.2M in commitments, with Blue Water again taking part.6 GenomeWeb put Ansa's total at "at least $136.4 million" after that round; adding $71.5M gives $207.9M by our arithmetic, against the $211M in the release, a gap of about $3M that the release does not explain.61 Fierce Pharma put the total at "more than $134 million" after the Series B, which would widen the gap to about $5.5M, so the baseline is not settled and the $211M rests on the company's release alone.7 Fierce Pharma noted at the time that Twist Bioscience and DNA Script also follow the enzymatic route.7

PitchBook's profile for Blue Water Life Science Fund (website bluewaterlifescienceadvisors.com, which we take to be the same firm) classes it as a Larkspur, California hedge fund manager founded in 2017. The profile lists 13 investments, including Ansa (2022 and October 2025), alongside Visby Medical, Karius, Sonendo and Vizgen; PitchBook's profile is a preview and shows no deal sizes.8 Cornell's biography in the release cites more than 25 years in capital markets, including research roles covering life science tools.1 Illumina Ventures was one of the participants in a $27M financing for Lightcast, a single-cell analysis tools company, led by ARCH Venture Partners in April 2026.9 Lightscape says it backs pre-seed to Series B companies across compute, robotics, infrastructure software, data and applied AI; Ansa is not a listed sector, though Lightscape pitches reliable DNA synthesis as infrastructure for AI-driven research.2

Competition is moving. On 30 October Azenta announced an exclusive licence to Elegen's cell-free DNA manufacturing technology and the acquisition of SynPlexity for its GENEWIZ business, saying SynPlexity's gene libraries address the scale of biological design, including AI-generated designs.10 Dealroom News, in a summary based on the company release, framed the key test as whether Ansa can turn its capacity and reliability claims into sustained demand; it adds no independent confirmation of the $211M total or the capacity claim.11

Why it matters: the round shows investors paying for reliable delivery of long synthetic DNA as AI-driven biology grows, but capacity, demand and fulfilment figures are company-reported, and rivals such as Azenta's GENEWIZ are expanding too.1410

Sources

  1. Ansa Biotechnologies Raises $71.5 Million in Oversubscribed Series C Round to Scale Guaranteed DNA Synthesis (Business Wire (Ansa Biotechnologies))
  2. The DNA Behind AI-Enabled Discovery (Lightscape Partners)
  3. Ansa raises $71.5M for DNA service with shipping guarantees (Captables)
  4. Researchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering Platform (BioSpace (Business Wire))
  5. Ansa Biotechnologies ties up $68M for DNA synthesis platform (Fierce Biotech)
  6. Ansa Biotechnologies Raises $54.4M in Series B Financing Round (GenomeWeb)
  7. Ansa snares $54.4M in series B to boost its DNA synthesis platform (Fierce Pharma)
  8. Blue Water Life Science Fund investment portfolio (PitchBook)
  9. Lightcast Raises $27 Million and Adds Industry Veteran to Accelerate Commercialization of Envisia Platform (VentureBeat (Business Wire))
  10. Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities (Azenta (PR Newswire))
  11. Ansa raises $71.5M Series C to scale guaranteed DNA synthesis (Dealroom News)